SILO PHARMA, INC. APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition
SILO PHARMA, INC. (SILO) reported APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition of -$1.89 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital › APIC, Share-Based Payment Arrangement, Increase for Cost Recognition
us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition · last filed 2026-08-13
- SILO PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-06-30 was -$1.89K.
- SILO PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2026-03-31 was $2.89K, a 65.08% decline year-over-year.
- SILO PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-09-30 was $1.78K, a 84.87% decline year-over-year.
- SILO PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for the quarter ending 2025-06-30 was -$1.14K.
- SILO PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2023 was $14.13K, a 87.28% decline from fiscal 2022.
- SILO PHARMA, INC. apic, share-based payment arrangement, option, increase for cost recognition for fiscal 2022 was $111.01K.
| Period end | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$1.89K 10-Q · filed 2026-08-13 | $1.00K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2026-03-31 | $2.89K 10-Q · filed 2026-08-13 | |||
| 2025-12-31 | $3.41K POS AM · filed 2026-04-14 | |||
| 2025-09-30 | $1.78K 10-Q · filed 2025-11-13 | $641.00 derived: sum of 2 quarters · filed 2026-08-13 | $8.93K derived: sum of 3 quarters · filed 2026-08-13 | |
| 2025-06-30 | -$1.14K 10-Q · filed 2026-08-13 | $7.14K derived: sum of 2 quarters · filed 2026-08-13 | ||
| 2025-03-31 | $8.29K 10-Q · filed 2026-08-13 | |||
| 2024-12-31 | $8.65K POS AM · filed 2026-04-14 | |||
| 2024-09-30 | $11.77K 10-Q · filed 2025-11-13 | -$6.31K derived: sum of 2 quarters · filed 2025-11-13 | $26.02K derived: sum of 3 quarters · filed 2025-11-13 | |
| 2024-06-30 | -$18.08K 10-Q · filed 2025-11-13 | $14.25K derived: sum of 2 quarters · filed 2025-11-13 | ||
| 2024-03-31 | $32.33K 10-Q · filed 2025-11-13 | |||
| 2023-12-31 | $14.13K 10-K · filed 2025-03-28 | |||
| 2023-09-30 | $4.24K 10-Q · filed 2024-11-12 | $8.47K derived: sum of 2 quarters · filed 2024-11-12 | $12.71K derived: sum of 3 quarters · filed 2024-11-12 | |
| 2023-06-30 | $4.24K 10-Q · filed 2024-11-12 | $8.47K derived: sum of 2 quarters · filed 2024-11-12 | ||
| 2023-03-31 | $4.24K 10-Q · filed 2024-11-12 | |||
| 2022-12-31 | $111.01K 10-K · filed 2024-03-25 | |||
| 2022-09-30 | $7.56K 10-Q · filed 2023-11-13 | $22.67K derived: sum of 2 quarters · filed 2023-11-13 | $67.68K derived: sum of 3 quarters · filed 2023-11-13 | |
| 2022-06-30 | $15.11K 10-Q · filed 2023-11-13 | $60.12K derived: sum of 2 quarters · filed 2023-11-13 | ||
| 2022-03-31 | $45.01K 10-Q · filed 2023-11-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Alaunos Therapeutics, Inc. (TCRT) | United States | $0.003B | -1.44 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |